Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount.
BASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
That added production capacity for Eli Lilly's obesity pill, orforglipron, is crucial as the company races to file for its…
South Korean biopharmaceutical company Celltrion said it would invest at least $1 billion to acquire a plant from Eli Lilly in…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the…
